COPD affects the expression of vascular endothelial growth factor (VEGF) in the circulation, suggesting that the anti-VEGF and anti-VEGF receptor inhibitors may be effective in NSCLC patients with COPD. This evidence concerns the gene VEGFA and chronic obstructive pulmonary disease.